Literature DB >> 15347637

Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Venkata G Meka1, Howard S Gold, Amy Cooke, Lata Venkataraman, George M Eliopoulos, Robert C Moellering, Stephen G Jenkins.   

Abstract

OBJECTIVES: Linezolid resistance in rare isolates of Staphylococcus aureus has been associated with G2576T mutations in domain V of the 23S rRNA gene. We report the analysis of a clinical S. aureus isolate that developed linezolid resistance (MIC of linezolid of 12 mg/L) after a 25 day course of the drug. Sequencing identified G2576T mutations in four of the five copies of the 23S rRNA gene.
METHODS: To examine the stability of this resistance, we serially passaged this original isolate 60 times over a 75 day period on antimicrobial-free medium.
RESULTS: After 30 passages, the MIC of linezolid had decreased to 8 mg/L and only two of the five copies of the 23S rRNA gene contained the G2576T mutation. After 60 passages, the MIC of linezolid fell to 2 mg/L and only one of the five 23S rRNA gene copies contained the mutation. The original and two passaged staphylococci were indistinguishable by pulsed-field gel electrophoresis.
CONCLUSIONS: In the absence of antibiotic pressure, linezolid resistance was unstable in a clinical isolate that did not have all copies of the 23S rRNA gene mutated, although a single copy of mutant rDNA was maintained. Gene conversion was probably the mechanism for this reversion, using the wild-type 23S rRNA gene sequences to replace the G2576T mutation by homologous recombination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347637     DOI: 10.1093/jac/dkh423

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

Authors:  Carmen Betriu; Gracia Morales; Icíar Rodríguez-Avial; Esther Culebras; María Gómez; Fátima López-Fabal; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 3.  Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Heterogeneous macrolide resistance and gene conversion in the pneumococcus.

Authors:  Nicole Wolter; Anthony M Smith; David J Farrell; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.

Authors:  Jamela Seedat; Günther Zick; Ingo Klare; Carola Konstabel; Norbert Weiler; Hany Sahly
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

6.  Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.

Authors:  Silke Besier; Albrecht Ludwig; Johannes Zander; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

7.  In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.

Authors:  Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Compensation of fitness costs and reversibility of antibiotic resistance mutations.

Authors:  Pia Schulz zur Wiesch; Jan Engelstädter; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 9.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

Review 10.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.